Compare ICMB & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | CELU |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.8M | 34.5M |
| IPO Year | N/A | N/A |
| Metric | ICMB | CELU |
|---|---|---|
| Price | $3.05 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 43.4K | 31.7K |
| Earning Date | 03-24-2026 | 11-14-2025 |
| Dividend Yield | ★ 16.88% | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | $17,931,778.00 | ★ $40,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | $76.00 |
| P/E Ratio | $8.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $1.00 |
| 52 Week High | $3.47 | $4.35 |
| Indicator | ICMB | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 63.48 | 44.78 |
| Support Level | $2.88 | $1.20 |
| Resistance Level | $3.12 | $1.31 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 88.89 | 41.75 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.